open access

Vol 11, Supp. K (2015)
Case report
Published online: 2016-04-24
Get Citation

Gefitinib as a first line therapy in a patient with non small cell lung cancer STRESZCZENIE

Paweł Badurak

open access

Vol 11, Supp. K (2015)
CASE REPORTS
Published online: 2016-04-24

Abstract

A case report of a 65-year-old woman who received gefitinib as a first line therapy for adenocarcinoma of the lung between March 2013 and October 2014 at Oncology Centre M. Sklodowska-Curie Memorial Institute in Warsaw. The patient was diagnosed as clinical stage IV (both lung metastasis). The treatment was well tolerated. The clinical and radiological benefits of EGFR-tyrosine kinase inhibitor (TKI) have been observed in the above patient with EGFR mutation.

Abstract

A case report of a 65-year-old woman who received gefitinib as a first line therapy for adenocarcinoma of the lung between March 2013 and October 2014 at Oncology Centre M. Sklodowska-Curie Memorial Institute in Warsaw. The patient was diagnosed as clinical stage IV (both lung metastasis). The treatment was well tolerated. The clinical and radiological benefits of EGFR-tyrosine kinase inhibitor (TKI) have been observed in the above patient with EGFR mutation.

Get Citation

Keywords

gefitinib, first line therapy, non small cell lung cancer

About this article
Title

Gefitinib as a first line therapy in a patient with non small cell lung cancer STRESZCZENIE

Journal

Oncology in Clinical Practice

Issue

Vol 11, Supp. K (2015)

Article type

Case report

Published online

2016-04-24

Keywords

gefitinib
first line therapy
non small cell lung cancer

Authors

Paweł Badurak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl